MINNEAPOLIS, June 15 /PRNewswire-FirstCall/ -- ATS Medical, Inc. is looking forward to its participation in the 4th Biennial Meeting of the Society of Heart Valve Disease. The event runs June 15-18, 2007 and will attract cardiovascular surgeons from around the world to its venue at the Hotel Pennsylvania in New York City.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)
Noteworthy for ATS Medical are several presentations focusing on products in their expanding portfolio of cardiac surgery offerings.
-- "Effects of Aortic Prosthetic Valve Design on Coronary Flow Velocity Profiles" from the John Radcliffe Hospital in Oxford, United Kingdom reports on improvements in coronary flow seen with the ATS 3f Aortic Bioprosthesis. -- "Five Years Clinical Experience with the 3f Stentless Aortic Bioprosthesis" from Johann Wolfgang Goethe University in Frankfurt, Germany documents excellent midterm clinical performance, improved implantability and excellent restoration of coronary blood flow. -- "Hemodynamic and Clinical Outcome in Bovine and Equine Stentless Pericardial Aortic Valve Bioprostheses: Three Years Follow-up" from the University of Berlin Charite demonstrated hemodynamic benefits for the ATS 3f Aortic Bioprosthesis. -- "Ten-year Results of the ATS Open Pivot Bileaflet Heart Valve" from the National Cardiovascular Center in Osaka, Japan documents the low long term complication rates associated with ATS mechanical valve implantation. -- "Cryomaze Using Argon-based Cryoablation Is Highly Effective Therapy During Complex Valve Procedures" describes the favorable experience of Harold G. Roberts, MD and colleagues from South Florida Cardiovascular Surgical Associates in Ft. Lauderdale, Florida, using CryoCath technology for the surgical ablation of cardiac arrhythmias.
Michael D. Dale, Chairman, President and CEO of ATS Medical noted, "Surgeons rely heavily on the reported experience of their colleagues in making product decisions. A critical component in our success going forward will lie in our ability to foster an environment and product mix that attracts the interest of physicians and scientists who are respected researchers. The activity surrounding products in our portfolio at this year's Society of Heart Valve Disease Meeting is ample evidence that we are making strides towards that objective."
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The company, global in scope, has been headquartered in Minneapolis, Minnesota. More than 135,000 ATS Open Pivot(R) Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3F(R) brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(TM) annuloplasty products for heart valve repair, SurgiFrost(R) and FrostByte(R) products for surgical cryoablation of cardiac arrhythmias, RTI-Cardiovascular for allograft tissue services, and the development of PARSUS blood filtration technology. The ATS Medical web site is http://www.atsmedical.com.
Safe Harbor
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3F Therapeutics, regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2006.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comATS Medical, Inc.CONTACT: Michael Dale, President-CEO, +1-763-553-7736, or Michael Kramer,Senior Director of Finance, +1-763-557-2222, both of ATS Medical, Inc.; orInvestors, Jennifer Beugelmans, +1-646-201-5447, or Doug Sherk,+1-415-896-6820, or Media, Jennifer Saunders, +1-646-201-5431, all for ATSMedical, Inc.
Web site: http://www.atsmedical.com/
